Study:
Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma
Rationale:
Drugs used in chemotherapy, such as carboplatin, cyclophosphamide, etoposide, and
doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either
by killing the cells or by stopping them from dividing. Isotretinoin may help neuroblastoma
cells become more like normal cells, and grow and spread more slowly. Giving combination
chemotherapy with or without isotretinoin before surgery may make the tumor smaller and
reduce the amount of normal tissue that needs to be removed. It is not yet known which
treatment regimen is more effective in treating young patients with neuroblastoma.
Purpose:
This phase III trial is comparing different regimens of combination chemotherapy
and surgery with or without isotretinoin to see how well they work in treating young
patients with neuroblastoma.
Study Status: Active, not recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Neuroblastoma |
Drug: carboplatin
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: topotecan hydrochloride |
Phase 3 |
Verified by
Children`s Oncology Group
July, 2011
Sponsored by: Children`s Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00499616
Study Type: Interventional
Study Design: Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Clare Twist, MD., Study Chair
Mary Lou Schmidt, MD.,